drugset / Trial / NCT07396090
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, immunogenicity and preliminary efficacy of engineered dendritic cells（eDCs）loaded with mKRAS antigen (CAT-101) alone or in combination with Tislelizumab (anti-PD-1 monoclonal antibody) among participants with KRAS-G12C/D/R/V mutated advanced pancreatic cancer and other solid tumors.
Timeline
- Start
- 2026-01-20
- Primary completion
- 2026-10-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAT-101 | Cell therapy | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.